NCT03156153View on ClinicalTrials.gov

A Study of Bumetanide for the Treatment of Autism Spectrum Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 24, 2017

Primary Completion Date

July 8, 2019

Study Completion Date

July 10, 2019

Conditions
Autism Spectrum Disorder
Interventions
DRUG

Bumetanide

bumetanide tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm

DRUG

Placebo

placebo tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm

Trial Locations (1)

200000

Xinhua Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Jiao Tong University School of Medicine

OTHER

lead

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT03156153 - A Study of Bumetanide for the Treatment of Autism Spectrum Disorders | Biotech Hunter | Biotech Hunter